EF
SUPN icon

Empowered Funds’s Supernus Pharmaceuticals SUPN Stock Holding History

Empowered Funds’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-5,107
Closed -$264K – 2280
2026
Q1 		$264K Buy
+5,107
New +$260K ﹤0.01% 1883
2025
Q2 		– Sell
-48,045
Closed -$1.57M – 1848
2025
Q1 		$1.57M Buy
48,045
+6,619
+16% +$235K 0.02% 844
2024
Q4 		$1.5M Buy
+41,426
New +$1.46M 0.02% 840
2024
Q1 		– Sell
-26,350
Closed -$763K – 1439
2023
Q4 		$763K Buy
+26,350
New +$699K 0.02% 874
2023
Q3 		– Sell
-52,192
Closed -$1.57M – 1265
2023
Q2 		$1.57M Sell
52,192
-72,286
-58% -$2.53M 0.06% 489
2023
Q1 		$4.51M Buy
+124,478
New +$4.79M 0.27% 113

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Empowered Funds's SUPN Position: Q2 2026 in Review

Empowered Funds sold out of Supernus Pharmaceuticals (SUPN) in Q2 2026, closing a stake of 5,107 shares — an estimated $264K sold.

Empowered Funds first reported a position in SUPN in Q1 2023 and held it in 6 quarters. The position peaked at $4.51M in Q1 2023. 335 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • Empowered Funds reported no remaining Supernus Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Empowered Funds sold 5,107 Supernus Pharmaceuticals shares in Q2 2026, an estimated $264K.
  • Empowered Funds first reported a position in Supernus Pharmaceuticals in Q1 2023 and held it in 6 quarters.
  • Empowered Funds's Supernus Pharmaceuticals position peaked at $4.51M in Q1 2023.
  • 335 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Empowered Funds's 13F filing for Q2 2026, filed 17 Aug 2026.